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Local increases in blood flow - ‘hypoxic vasodilation’ - confer cellular protection in the 
face of reduced oxygen delivery. The physiological relevance of this response is well 
established, yet ongoing controversy surrounds its underlying mechanisms. We sought to 
confirm that early hypoxic vasodilation is a nitric oxide (NO)-mediated phenomenon and 
to study putative pathways for increased levels of NO, namely production from NO 
synthases, intravascular nitrite reduction, release from pre-formed stores, and reduced 
deactivation by cytochrome c oxidase. Experiments were performed on spontaneously 
breathing, anaesthetized, male Wistar rats undergoing short-term systemic hypoxaemia, 
who received pharmacological inhibitors and activators of the various NO pathways. 
Arterial blood pressure, cardiac output, tissue oxygen tension and the circulating pool of 
NO metabolites (oxidation, nitrosation and nitrosylation products) were measured in 
plasma and erythrocytes. Hypoxaemia caused a rapid and sustained vasodilation, which 
was only partially reversed by non-selective NOS inhibition. This was associated with 
significantly lower plasma nitrite, and marginally elevated nitrate levels, suggestive of 
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produced significant vasodilation and increased nitrosylation during hypoxaemia that 
could not be reversed by NO scavenging. Methodological issues prevented assessment of 
the contribution, if any, of reduced deactivation of NO by cytochrome c oxidase. In 
conclusion, acute hypoxic vasodilation is an adaptive NO-mediated response that is 
conferred through bioactive metabolites rather than free NO from haemoglobin-
mediated reduction of nitrite.  
Word count: abstract: 231; text: 4916 
Abbreviation list: ABP: arterial blood pressure; CPTIO: 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-
imidazoline-1-oxyl-3-oxide; HIF: hypoxia-inducible factor; L-NAME: N(G)-nitro-L-arginine methyl ester; 
NEM: N-ethylmaleimide; NO-Hb: nitrosyl-haemoglobin; NOS: nitric oxide synthase; POE-Hb: pyridoxylated 
haemoglobin poly-oxoethylene conjugate; RNNO: N-nitrosamines; RSNO: S-nitrosothiols; RXNO: sum of 
nitrosation products; SEITU: S-ethyl-isothiourea; sGC: soluble guanylate cyclase; SVR: systemic vascular 
resistance 
Keywords:  Hypoxic vasodilation; Nitric oxide; Nitrite; Hypoxaemia. 
 
Key points: 
 Hypoxia increases blood flow through vasodilation, an adaptive response that 
increases oxygen availability to tissues. 
 This response is likely mediated by nitric oxide (NO); different mechanisms have 
been postulated (increased de novo synthesis, release from pre-formed stores, reduced 
inactivation), but precise mechanisms remain controversial.  
 In a short-term rodent model, hypoxaemia was associated with hypotension and 
lower plasma nitrite levels suggestive of nitrite bioinactivation; this was only partially 
reversed by NO synthase inhibition. Administration of sodium nitrite produced marked 
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 Early hypoxic vasodilation is mediated by a complex interaction of multiple NO-
related species, rather than by nitric oxide from haemoglobin-mediated reduction of 
nitrite per se. 
 NO and its metabolites play a pivotal role in the body’s initial adaptation to an acute 
decrease in oxygen supply, likely offering protection against a supply-demand mismatch.  





Mammals crucially require oxygen (O2) as the terminal electron acceptor in the 
mitochondrial respiratory chain to provide sufficient energy for cell metabolism, organ 
function and survival (Brand, 2005). Any serious imbalance between O2 delivery and 
consumption can lead to a state of energetic crisis (Taylor & Pouyssegur, 2007). This is a 
critical factor underlying cell death (Brunelle & Chandel, 2002) and organ failure (Rixen & 
Siegel, 2005). 
Several complementary mechanisms work in concert to protect the tissues in the face of 
reduced O2 delivery. These include measures to facilitate O2 availability such as local 
increases in blood flow - ‘hypoxic vasodilation’ (Roy & Brown, 1880; Dreyer, 1926; Hackel 
et al., 1954; Heistad & Wheeler, 1970; Rowell & Blackmon, 1987, 1989), with flow 
redistribution to ‘vital’ organs and increased recruitment of perfused microvessels (Tsai 
et al., 2003).  In parallel, additional strategies are employed that include decreasing 
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generation of ATP, and modifying substrate availability and utilization, for example 
through the hormonal response to acute stress (Semenza, 2007). 
Nitric oxide (NO) is a key determinant of myocardial function and vascular tone. It is 
essential for both global regulation and regional distribution of blood flow and pressure 
(Welch & Loscalzo, 1994). NO also plays a crucial role in energy regulation and 
metabolism through its modulatory effects on mitochondrial activity, and on protein 
function through nitrosylation, nitrosation or nitration (Clementi et al., 1999; Jobgen et 
al., 2006; Cooper & Giulivi, 2007). NO levels in blood or tissues represent a balance 
between production/release and metabolism/bioinactivation.  
NO likely plays a key role in the body’s early adaptation to an acute energy supply-
demand mismatch. However, considerable controversy persists with respect to its 
sources and mechanisms of action (Umbrello et al., 2013). Using a short-term rodent 
model of systemic hypoxaemia, we sought to confirm that acute hypoxic vasodilation is a 
NO-mediated phenomenon, and to study the contribution of putative pathways known 
or suspected to enhance NO bioactivity, namely increased production from NO 
synthases, increased reduction of nitrite by red blood cells, increased release from pre-
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METHODS 
 
Male Wistar rats of approximately 300 g body weight were used in all experiments. 
Animals were purchased from Charles River (Margate, Kent, UK) and housed in cages of 
four on an alternating 12 h light–dark cycle, with free access to chow (2018 rodent diet, 
Harlan Teklad, Madison, WI, USA) and tap water. Prior to instrumentation, animals were 
allowed to acclimatize to the local environment for at least one week. All experiments 
were performed according to Home Office (UK) guidelines under the 1986 Animal 
(Scientific Procedures) Act with University College London Ethics Committee approval.  
Instrumentation and monitoring 
Spontaneously breathing animals were placed into a transparent plastic container and 
anaesthetised by 5% isoflurane (Baxter Healthcare, Thetford, UK) in room air. Following 
abolition of the righting reflex, animals were placed in the supine position onto a heated 
mat to maintain rectal temperature at 37 °C. Under 2-2.5% isoflurane, the left common 
carotid artery and right internal jugular vein were located, isolated and cannulated using 
0.96 mm outside diameter PVC tubing catheter (Biocorp Ltd, Huntingdale, Australia). The 
arterial line was connected to a pressure transducer (Powerlab, AD Instruments, 
Chalgrove, UK) for continuous monitoring of arterial blood pressure (ABP). The venous 
line was used for subsequent administration of fluids and drugs. A tracheostomy was 
sited using 2.08 mm external diameter polyethylene tubing (Portex Ltd, Hythe, UK) to 
secure and suction the airway. This was connected to a T-piece to maintain anaesthesia 
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Continuous monitoring of muscle tissue PO2 (tPO2) levels was obtained by the use of 
Large Area Surface (LAS™) oxygen sensors (0.7 mm diameter) connected to the Oxylite™ 
tissue monitoring system (Oxford Optronix, Abingdon, Oxon, UK), as described in detail 
elsewhere (Dyson et al., 2007). Briefly, the sensor sends short pulses of light (475 nm) 
along a fibreoptic cable to a platinum-complex fluorophore situated at the probe tip. This 
provides an 8 mm2 surface area in contact with the tissue for tPO2 measurement. Upon 
interaction with oxygen, the fluorophore emits light (600 nm) back to the detection unit, 
the lifetime of which is inversely proportional to the local PO2 concentration within the 
tissue of interest. Unlike polarographic techniques, oxygen is not consumed during the 
measurement process; moreover, as the fluorescence decay is longer at lower values of 
PO2, highly accurate measurements can be made in a hypoxic environment. A small 
incision was made at mid-thigh level, and the sensor inserted into the vastus lateralis 
muscle to a depth of 10 mm using an 18-gauge cannula for guidance (Venflon™, Becton 
Dickenson, Franklin Lakes, NJ, USA). The sensor was then withdrawn by 2 mm to prevent 
erroneous measurements resulting from local haematoma. This was verified by seeing a 
rapid response in tPO2 following a change in inspired O2. Arterial blood pressure (ABP) 
and muscle tPO2 measurements were continuously monitored and recorded onto a 
computer using a Powerlab system and Chart 5.0 acquisition software (AD Instruments, 
Chalgrove, UK). 
Isoflurane anaesthesia was reduced to 1.2% for the remainder of the experiment. Post-
instrumentation, intravascular volume optimization was achieved by repeated 0.5 ml 
intravenous challenges of 0.9% saline given over 10 s every 5 min until ABP failed to 
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10 ml/kg/h for the duration of the experiment to ensure adequate filling conditions 
throughout. All animals were allowed to stabilize for at least 30 min to achieve constant 
baseline physiological variables before the beginning of the experiment.  
At pre-defined time points, arterial blood samples (0.2 ml) were collected into 
heparinized capillary tubes for blood gas analysis (ABL-625 analyzer, Radiometer, 
Copenhagen, Denmark). Blood (0.5 ml) was also collected into tubes containing N-
ethylmaleimide (NEM; 10 mM) and EDTA (2.5 mM) to prevent artificial thiol nitrosation 
and to minimize transition metal-catalyzed RSNO degradation and trans-nitrosation 
reactions (Marley et al., 2000). Plasma and erythrocytes were then obtained by 
centrifugation at 800g at 4°C for 10 min. Both plasma and erythrocytes were immediately 
frozen in liquid nitrogen and stored at -80 °C for subsequent analysis. 
Transthoracic echocardiography was performed using a Vivid 7 Dimension™ machine (GE 
Healthcare, Bedford, UK) with a 14 MHz probe recording at a depth of 0-2 cm. Aortic 
blood flow velocities were determined immediately before the right carotid artery 
bifurcation using pulsed-wave Doppler; the direction of blood flow was confirmed by 
colour Doppler imaging. Stroke volume (SV) was determined as the product of the 
velocity time integral (VTI) and vessel cross-sectional area (∏ x [0.5 x diameter]2). Rats of 
this size have an aortic diameter of 0.26 cm (Slama et al., 2003), thus a cross-sectional 
area of (0.13)2 x ∏ was assumed for all animals studied. Heart rate (HR) was determined 
by measuring the time between six consecutive cycles from the start of each Doppler 
trace to account for variation with respiration. Cardiac output (CO) was determined as 
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pressure divided by CO. The O2 content in the arterial blood and global O2 delivery were 
calculated using standard formulae. 
Experimental protocols 
Modulation of the various NO pathways was achieved through separate studies (Figure 
1). For each experimental condition, after recording of baseline haemodynamic variables 
and blood sampling for NO metabolite determination (BL), animals were randomized to 
either breathing room air (N) or a hypoxic mixture (H) at an inspired oxygen 
concentration (FiO2) of 0.125. They were then allowed to stabilize for 10 minutes. 
Animals (six hypoxic and six normoxic per group) were then randomized into one of the 
following groups:  
i) sham, which only received the background infusion of 0.9% saline; 
ii) systemic vasoconstriction, using an intravenous infusion of norepinephrine at a rate 
of 1.5 µg/kg/min 
iii) NOS inhibition, where animals received a 1.5 mg/kg/min infusion of the potent, non-
selective NOS inhibitor S-ethyl-isothiourea (SEITU) (Southan et al., 1995);  
iv) nitrite (NO2
-) administration, where animals received a 250 µg/kg/min infusion of 
sodium nitrite, NaNO2 (Badejo et al., 2010);  
v) a combination of NOS inhibition with SEITU, and NaNO2 administration (doses as 
above);  
vi) non-haem NO scavenging, using an infusion of the scavenger 2-(4-carboxyphenyl)-
4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide (C-PTIO) (Yoshida et al., 1994) 
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vii) haem-based NO scavenging, where animals received a continuous infusion (50 
mg/kg/h) of pyridoxylated haemoglobin poly-oxoethylene (POE-Hb) (Kida et al., 
1995).  
To avoid any possible confounding effect, drug concentrations were calculated so that all 
animals received at total of 10 ml/kg/h of intravenous fluid. At the end of each 
experiment (30’), another aliquot of blood was drawn for the determination of NO 
metabolites. All drugs used were purchased from Sigma-Aldrich (Gillingham, Dorset, UK) 
with the exception of norepinephrine (Abbott Labs, Maidenhead, UK). POE-Hb was kindly 
donated by Apex Bioscience (Chapel Hill, NC, USA), and dissolved in 0.9% saline.  
Drug doses were selected after extensive exploratory dose-response experiments 
(Supplementary Figure S1). We chose a dose of SEITU for subsequent study that gave an 
approximate 40 mmHg rise in ABP in normoxic rats. Notably, no further increases in 
blood pressure were observed above this dose in either normoxic or hypoxic animals. We 
also attempted to modulate NO metabolism by altering the redox state of cytochrome c 
oxidase through administration of either hydrogen sulphide (given as NaHS) or sodium 
azide (both 10-8 to 10-2 g/kg/min). Unfortunately, major side-effects (severe 
haemodynamic instability leading to premature death) precluded in vivo study of this 
pathway. 
Figure 1b depicts the experimental schedule. Blood pressure and muscle tissue oxygen 
tension were monitored continuously. Echocardiography and blood gas analysis was 
performed at baseline, 10 and 30 minutes with sampling for plasma and erythrocyte 
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experiments, additional echocardiography and blood gas analysis was performed at 20 
minutes before administration of sodium nitrite. 
After analysis of the results, we performed two sets of additional experiments to better 
understand the mechanisms underlying our findings. The hypotheses we set out to test 
were: i) whether the vasodilation seen under hypoxia was caused by increased levels of 
NO per se or if a NO-related compound could play a role and ii) similarly, whether the 
vasodilating effect of nitrite in hypoxia was caused by increased levels of NO per se or if a 
NO-related compound could play a role. We thus treated two groups of hypoxic animals 
(n=6 each) with a combination of i) NOS inhibition followed by a continuous infusion of 
POE-Hb and ii) NOS inhibition and NaNO2 administration followed by a continuous 
infusion of POE-Hb; all drugs were used at the same doses as previously described. To 
avoid POE-Hb oxidation, the latter experiment required separate venous access for the 
administration of both drugs: in this group, SEITU and NaNO2 were administered via the 
jugular line. The left femoral vein was also cannulated for administration of POE-Hb.  
Biochemical analyses 
Frozen sample aliquots were thawed just before use. Plasma was used undiluted while 
the erythrocyte pellet was subjected to hypotonic lysis in cold aqueous NEM/EDTA 
(10/2.5 mM; 1:4 v/v) immediately before analysis. The concentration of nitroso 
compounds was assessed using group-specific reductive denitrosation by iodine-iodide in 
glacial acetic acid, with subsequent detection of liberated NO into the gas phase by its 
chemiluminescent reaction with ozone (Feelisch et al., 2002). ‘RSNO’ signifies mercury-
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resistant nitroso adducts and may include N-nitrosamines and metal nitrosyls other than 
NO-haem species. ‘RXNO’ represents the total pool of nitrosated species (i.e. the sum of 
RSNOs and RNNOs). NO-haem species in erythrocytes (nitrosylhaemoglobin) were 
determined by parallel injection of replicate aliquots of blood homogenates into a 
solution of 0.05 M ferricyanide in PBS at pH 7.5 and 37˚C (Bryan et al., 2004). This 
method employs one-electron oxidation rather than reduction to achieve denitrosation, 
with the liberated NO being quantified by gas-phase chemiluminescence (CLD 77 AM, Eco 
Physics, Ann Arbor, MI, USA). Nitrate and nitrite were quantified by ion chromatography 
with on-line reduction of nitrate to nitrite and post-column Griess diazotization (ENO20 
Analyzer; Eicom, Kyoto, Japan) (Rassaf et al., 2002) . 
Statistical Analysis 
All data are presented as means ± SEM (n=6 per group) unless otherwise specified. 
Statistics were performed on raw data using a repeated measures two-way ANOVA 
followed by Tukey’s post-hoc test (SigmaStat 11.0, Systat Software Inc, San Jose, CA) to 
compare multiple groups at multiple time points or unpaired Student’s t test to compare 
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RESULTS 
Model characterisation and effects of hypoxia 
Hypoxia (12.5% O2) significantly reduced arterial PO2 and haemoglobin saturation (Table 
1). Muscle tPO2 levels halved. Despite an unchanged respiratory rate, hypoxia was 
associated with reduced PaCO2, but similar arterial pH. Though tidal volumes were not 
formally measured, there was an obvious increase in chest wall excursion.  
Blood pressure fell significantly during hypoxia, and this was maintained over time 
despite no significant change in either stroke volume or heart rate (Figure 2, Suppl Fig. 
S1). As a consequence, systemic vascular resistance (SVR) was significantly lower in the 
hypoxic group. Global oxygen delivery was reduced by half, and blood lactate levels 
increased significantly (Table 1). 
Norepinephrine, titrated to increase mean ABP by 40 mmHg above normoxic levels, 
failed to reach this target under hypoxia (Fig. 2 and Table 1). Whereas this agent 
increased SVR in the normoxic group, it had little effect during hypoxia. HR was 
significantly increased by norepinephrine in both groups to the same extent. Oxygen 
delivery increased in both groups, though failed to reach baseline levels in the hypoxia 
group. Lactate levels were lower than during hypoxia alone, and similar to that measured 
in normoxic sham animals. 
Haemodynamic effects of the modulation of the NO system (Figure 2) 
Non-selective NOS inhibition with SEITU increased ABP to a greater extent in normoxic 
compared to hypoxic animals. A similar pattern was observed with the structurally 










This article is protected by copyright. All rights reserved. 13
significantly reduced cardiac output, mainly through its effect on stroke volume, hypoxic 
animals showed a lesser fall. Oxygen delivery was substantially reduced but did not differ 
between the two groups. Lactate levels increased to a greater extent in hypoxic animals 
treated with SEITU compared to that seen during hypoxia alone.  
Although nitrite administration had only a mild hypotensive effect in either normoxia or 
hypoxia, stroke volume increased in the hypoxia group and vascular resistance fell 
significantly, indicating further vasodilatation. This resulted in an overall oxygen delivery 
that was similar to the normoxic group treated with nitrite, although lactataemia was 
significantly greater. When nitrite was given after non-selective NOS inhibition with 
SEITU, the hypotensive effect was significantly more pronounced under hypoxic 
conditions. 
NO scavenging with C-PTIO had a greater effect on blood pressure in the normoxic group. 
Cardiac output also significantly increased with C-PTIO in normoxia, mainly through an 
increase in HR. On the other hand, the haem-based NO scavenger POE-Hb produced 
similar changes in blood pressure in both groups, though ABP values did not reach the 
levels obtained with NOS blockade or norepinephrine. 
When an NO scavenger was added after NOS inhibition in the hypoxic group, ABP failed 
to increase further (mean change +10.7 mmHg, p=0.799), with no changes seen in either 
cardiac output (mean increase 11.1 ml/min, p=0.478) nor SVR (mean increase 0.60 
mmHg/(ml/min), p=0.247). Similarly, when an NO scavenger was added after NOS 
inhibition and nitrite administration in the hypoxic group, ABP failed to increase (mean 
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11.7 ml/min, p=0.424) or SVR (mean increase 0.09 mmHg/(ml/min), p=0.982) 
(Supplementary Figure S3). 
Plasma NO metabolites (Figure 3, Table 2) 
Despite similar concentrations of circulating total NO oxidation products, 30 minutes of 
hypoxia significantly reduced plasma nitrite levels. Nitrate levels did not change 
significantly at this time point. Administration of norepinephrine resulted in lower plasma 
levels of nitrite and nitrate compared to the sham-treated groups, with no differences 
between normoxia and hypoxia. On the other hand, NOS inhibition reduced plasma 
nitrite levels during normoxia, but without any further reduction during hypoxia, whereas 
the concentration of total nitrosation products (RXNO) increased. S-nitrosothiols (RSNOs) 
accounted typically for less than half of the RXNO signal, and that this ratio didn’t change 
much under any of the experimental conditions applied. 
Administration of nitrite increased plasma nitrite by approximately 20-fold, with a near-
doubling of plasma nitrate and an increase in plasma total nitrosation products. 
However, no differences were seen between hypoxic and normoxic groups. Addition of 
NOS inhibition to nitrite did not change the plasma NO metabolite profile. 
Scavenging NO with C-PTIO reduced plasma nitrite levels to virtually zero, whereas 
nitrate levels were conserved. Plasma nitrosation products were also reduced, though no 
differences were seen between hypoxia and normoxia. Utilization of POE-Hb as the NO 
scavenger was associated with a similar profile of plasma oxidation products. However, in 
stark contrast to C-PTIO, plasma nitrosation products increased compared to sham in 
both normoxic and hypoxic animals. Table 2 shows the relative contribution of nitrite to 
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 Erythrocyte NO metabolites (Figure 4, Table 2) and nitrosyl-Hb (Figure 5) 
In sham animals, erythrocyte nitrite and nitrate levels were conserved during hypoxia, 
with no differences seen in nitrosation products. Norepinephrine reduced intracellular 
nitrite levels in normoxic animals but RSNO and RNNO remained largely unchanged. NOS 
inhibition by SEITU had no impact upon erythrocyte NO oxidation and nitrosation 
products, and no differences were seen between hypoxia and normoxia states. 
Notably, nitrite administration did not modify intraerythrocytic nitrite levels. However, 
nitrate concentrations were higher than in sham animals, particularly under hypoxic 
conditions. Nitrosyl haemoglobin levels were also higher during hypoxia. Similar results 
were seen when nitrite was co-administered with the NOS inhibitor, SEITU. NO 
scavenging was associated with lower intracellular nitrite levels, yet most other NO 
metabolites were unchanged. Of note, the NO metabolite profile observed in the 
presence of CPTIO was different from that of a typical NO-scavenger; besides the 
expected reductions in blood nitrite concentrations under normoxic and hypoxic 
conditions due to oxygen-independent conversion of NO to NO2, hypoxia was associated 
with increases in nitrosation products other than RSNOs and increases in 
nitrosylhaemoglobin. This suggests preferential formation of N-nitrosated species in red 
blood cells that act as potential NO-donors with this particular compound. Thus, care 
should be taken when CPTIO is used in in vivo studies, emphasizing the need to compare 
mechanistically distinct NO scavengers before reaching conclusions about the possible 
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 DISCUSSION 
Several complementary mechanisms protect the body’s tissues in the face of a 
reduced O2 delivery. These include redistribution of blood flow to ‘vital’ organs, 
and increased recruitment of perfused microvessels to facilitate O2 availability 
(Tsai et al., 2003). At the systemic level, the most evident adaptation to 
hypoxaemia involves an increase in blood flow - ‘hypoxic vasodilation’ (Roy & 
Brown, 1880; Dreyer, 1926; Hackel et al., 1954; Heistad & Wheeler, 1970; Rowell 
& Blackmon, 1987, 1989). This aims to compensate for the reduction in arterial O2 
content by attempting to maintain an acceptable O2 supply-demand balance. The 
sympathetic nervous system is activated with increased catecholamine levels, 
albeit with a reduced response to exogenous vasopressors (vascular 
hyporeactivity). 
Although the physiological relevance of hypoxic vasodilation is well established, 
ongoing controversy surrounds its underlying mechanisms. An increase in nitric 
oxide (NO) is strongly implicated. This key signalling and effector molecule is a 
major determinant of vascular tone, an important modulator of myocardial 
function, and essential for both global regulation and regional distribution of 
blood flow and pressure (Welch & Loscalzo, 1994). 
NO levels in blood and tissues represent a balance between production/release 
and metabolism/bioinactivation. Its best-recognized biosynthetic route is the L-
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alternative pathways are proposed, involving (i) nitrite and nitrate, oxidative end-
products traditionally considered to be inert (Modin et al., 2001), and (ii) S-
nitrosothiols (RSNO), the reaction products between reactive nitrogen oxide 
species and thiol residues (Diesen et al., 2008).  
Particularly under conditions of hypoxia, proteins from the haem-globin family (Gladwin 
& Kim-Shapiro, 2008) or from pteryn-based molybdenum enzymes (Li et al., 2008) may 
catalyze the reduction of nitrite to NO, beyond their conventional physiological functions. 
Release of NO from RSNO storage pools may also be enhanced under low oxygen 
conditions (Jia et al., 1996). These pathways may provide important alternative sources 
of NO where increased blood flow may be beneficial, such as during hypoxia, particularly 
recognizing the critical requirement for O2 as a cofactor for NOS. However, to date, many 
of these mechanisms have only been demonstrated in non-physiological conditions, 
either in vitro or ex vivo, or indirectly implicated by utilization of pharmacological tools. 
Thus, an open question still remains as to their in vivo (patho)-physiological relevance. 
The in vivo fate of NO is also highly complex; several catabolic pathways exist with 
varying relevance in different body compartments. The reaction with haemoglobin to 
form NO3
- constitutes the major catabolic pathway. However, in plasma in the presence 
of O2, the principal reaction is formation of NO2
- (Ignarro et al., 1993) occurring through 
oxidation by mitochondrial cytochrome c oxidase (Shiva et al., 2001; Pearce et al., 2002). 
An alternative theory for the hypoxia-induced increase in NO is reduced elimination. 
Using an in vitro model, Moncada and colleagues demonstrated that cytochrome c 
oxidase in its oxidized state constantly inactivates NO, contributing to its intracellular 
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state typical of hypoxia, an impaired inactivation would account for the witnessed 
increase in NO. 
NO acts at multiple sites within the body (Martinez-Ruiz et al., 2011). It promotes 
vasorelaxation either via activation of soluble guanylate cyclase (sGC) and subsequent 
generation of cyclic GMP (cGMP), or through S-nitrosation of critical thiols sited on ion 
channels. NO also inhibits the mitochondrial electron transport chain through direct 
competition with oxygen at Complex IV (cytochrome c oxidase), and via 
nitrosation/nitration of other respiratory chain complexes (Frost et al., 2005), ultimately 
causing a decrease in O2 consumption.  
As the vasodilating (Movahed et al., 2003) and metabolic (Frost et al., 2005) effects of NO 
are both enhanced during hypoxia, it likely plays a major role in re-equilibrating any O2 
supply-demand mismatch (Umbrello et al., 2013). Hypoxia-induced vasorelaxation may 
be reversed by scavenging NO (Pohl & Busse, 1989), or inhibiting sGC with methylene 
blue (Iwamoto et al., 1992). Whereas increased NO synthesis by NOS may be a potential 
cause of hypoxic vasodilation (Edmunds & Marshall, 2001; Hunter et al., 2003), others 
report an ineffectiveness of NOS inhibition on decreased hind limb resistance (Vallet et 
al., 1994) and dilation of small coronary arteries (Liu & Flavahan, 1997) induced by 
hypoxia.  
We set out to study mechanisms underlying hypoxic vasodilation in vivo using a well-
established short-term rodent model of systemic hypoxia (Dyson et al., 2007, 2009). We 
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that did not carry short-term lethality (Dyson et al., 2007). Our findings support the role 
of NO as a key mediator of hypoxic vasodilation.  
Hypoxaemia caused an immediate and sustained hypotension associated with muscle 
tissue hypoxia and increased glycolytic flux. Vasopressor hyporesponsiveness was 
confirmed by the limited increase in ABP with norepinephrine. Notably, hypoxia reduced 
ABP and SVR but had little effect on cardiac output: this may be explained by the 
balanced effect of an increased perfusion due to vasodilation and some degree of 
hypoxic myocardial depression, possibly NO-mediated (Brady et al., 1993; Mohan et al., 
1996).  
Non-selective NOS inhibition with SEITU reversed hypoxic vasodilation but failed to 
achieve ABP values obtained from normoxic, SEITU-treated animals; we observed a 
similar pattern using the non-selective NOS inhibitor L-NAME and infer the difference in 
blood pressure between normoxic and hypoxic rats is due to NO not generated by NOS 
but derived from other pathways (nitrite reduction or release from pre-formed nitroso-
pools). Hypoxia was associated with significantly lower plasma levels of nitrite, 
supporting the concept of increased NO production originating from nitrite reduction. 
When NOS was blocked by SEITU, plasma nitrite was lowered even under normoxic 
conditions. Most likely, this change is unrelated to nitrite reduction but a direct 
consequence of reduced NO production from NOS. Administration of nitrite caused little 
hypotensive effect in normoxia, and only small reductions of ABP under hypoxia. 
However, stroke volume and cardiac output, and thus SVR, were significantly higher in 
the hypoxic group, suggesting a stronger vasodilating effect of nitrite administration 
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being already low due to hypoxia alone. However, nitrite administration significantly 
increased nitrosyl haemoglobin generation during hypoxia, consistent with higher levels 
of NO production. When given after non-selective NOS-blockade with SEITU, nitrite 
caused a significantly greater hypotensive effect under conditions of hypoxia, 
accompanied by a further increase in nitrosyl haemoglobin levels.  
Experiments with NO scavengers could distinguish whether the vasodilating factor acting 
in hypoxia was due to intravascular generation of NO per se or one or more NO-related 
compound(s). Both C-PTIO and POE-Hb are specific extracellular NO scavengers and both 
increased ABP irrespective of the presence of hypoxia. A possible explanation is that NO 
produced by endothelial cells exerts its vasorelaxing activity by a paracrine effect on 
surrounding vascular smooth cells, with no transit into the bloodstream. However, the 
changes in the circulating pool of NO oxidation and nitration products during NO 
scavenging suggest that a portion of the NO generated in vascular tissue does get 
transferred to the bloodstream. Alternatively, NO does not exert its vasodilatory action 
directly, but rather through the action of other downstream mediators. A study 
performed under physiological conditions found that nitrite was not directly reduced to 
NO but instead modulated several different signalling pathways (Bryan et al., 2005). In 
addition to sGC activation, post-translational modifications typically associated with NO 
occur, such as the formation of nitrosated, nitrosylated and nitrated species (Bryan et al., 
2005; Perlman et al., 2009). Thus, nitrite may exert its signalling functions directly, 
without the need for intermediary formation of free NO. Hypoxia markedly potentiates 
tissue NO production from nitrite in a dose-dependent manner (Feelisch et al., 2008). 
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cluster and molybdenum-based reductases distributed among distinct subcellular 
compartments acting in a multifactorial and cooperative manner to catalyze the reaction. 
Acute hypoxia also reduced nitrite concentrations yet simultaneously enhanced the 
formation of NO metabolites such as RSNOs and RNNOs in an NO-independent manner, 
again consistent with a pathway that generates bioactive NO metabolites without the 
intermediacy of free NO. In this paradigm, conversion of nitrite to NO and the storage of 
NO bioactivity as RSNOs may both be constituents of a more complex regulatory 
mechanism of interaction of multiple NO-related species. To further test this hypothesis, 
and its in vivo relevance, we designed experiments whereby NO was scavenged after 
hypoxia and NOS inhibition ± nitrite administration. Notably, in both cases, blood 
pressure failed to increase upon NO scavenging, further supporting the hypothesis that 
actions of NO in hypoxia are mediated by NO metabolite signalling pathways rather than 
by NO directly. 
Our study has several limitations: first, we focused on the acute hypoxic response, which 
may present different mechanisms from the response to chronic hypoxia. However, ten-
fold higher levels of circulating NO products were found in Tibetan plateau residents 
compared to sea-level dwellers (Erzurum et al., 2007). This was associated with increased 
resting forearm blood flow, suggesting a NO-mediated adaptive mechanism that offsets 
the O2 lack caused by high altitude and which persists over time. Our rats were 
anaesthetized and spontaneously breathing, and responded to hypoxia with an increase 
in their ventilatory drive. The subsequent reduction in PaCO2 (compared to group-
matched normoxic rats) was, however, limited, and probably more representative of the 
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indeed complex. Studies have demonstrated that NO is a major, though not the sole, 
contributor to this response, (Liu & Flavahan, 1997), or that it acts within a network of 
synergistic factors (von Beckerath et al., 1991; Park et al., 1992). Indeed, some of our 
results may be explained by concomitant activation of other signalling pathways. Another 
limitation of our study is that changes in NO metabolite status have only been assessed in 
blood and not in the vasculature itself. While a contribution by NO generated in the 
vascular wall can thus not be entirely excluded, this is unlikely to have occurred under 
our experimental conditions as the high concentrations of the two NO scavengers used 
should have created a sink for NO that would be efficient enough to show clear reversal 
of the effects of nitrite – however, this is not what we observed. Regrettably, we were 
unable to explore the possibility that NO levels may be increased in hypoxia because of a 
reduced metabolism/bioinactivation. Although we tried several strategies to modulate 
the redox state of cytochrome c oxidase (namely azide and hydrogen sulphide 
administration), unavoidable side-effects prevented the in vivo construction of such a 
model. Due to these methodological constraints we cannot exclude that reduced 
inactivation of NO by cytochrome c oxidase may be an additional contributory factor. 
In conclusion, we demonstrated that short-term hypoxic vasodilation in vivo is an 
adaptive response mediated by NO. The mediator seems to act through bioactive 
metabolites, in a complex regulatory network of interaction of multiple NO-related 
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Figure 1: Sites of intervention and study protocol 
A: Pathways of NO production with identification of sites of action of inhibitors and 
activators used in the study. For details about the pathways, please refer to the text.  
NOS: Nitric Oxide synthase; RSNO: products of the nitrosation of critical thiol residues; 
sGC: soluble Guanylate Cyclase; NaNO2: sodium nitrite; NO2
-: nitrite anion; SEITU: non-
selective NOS inhibitor S-ethyl-isothiourea; L-NAME: non-selective NOS inhibitor N (G)-
nitro-L-arginine methyl ester; C-PTIO: organic NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-
tetramethyl-imidazoline-1-oxyl-3-oxide; POE-Hb: haem-based NO scavenger 
pyridoxylated haemoglobin poly-oxoethylene. The bolt denotes increase in the target 
concentration, the dashed line denotes a decrease, through enzymatic inhibition (SEITU) 
or conversion/direct scavenging (C-PTIO and POE-Hb).  
B: Study design showing doses and timings of pharmacological inhibitors and activators 
ABP: arterial blood pressure; BL: baseline measurement; N1/H1: measurement made 10 
min after randomisation to either hypoxia or normoxia; N2/H2: measurement made 20 
min after the commencement of pharmacological inhibitors or activators. BGA: arterial 
blood gas analysis; ECHO: echocardiography; tPO2: tissue (muscle) PO2. NaNO2: nitrite-
donor sodium nitrite; SEITU: non-selective NOS inhibitor S-ethyl-isothiourea; C-PTIO: 
organic NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-
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Figure 2: Haemodynamic effects of modulation of NO bioavailability 
NEPI: norepinephrine group; SEITU: non-selective NOS inhibitor S-ethyl-isothiourea 
group; NaNO2: nitrite-donor sodium nitrite group; C-PTIO: organic NO scavenger 2-(4-
carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide group; POE-Hb: haem-
based NO scavenger pyridoxylated haemoglobin poly-oxoethylene group.  
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Figure 3: Plasma metabolites related to oxidation of and nitrosation by NO 
NEPI: norepinephrine group; SEITU:  non-selective NOS inhibitor S-ethyl-isothiourea 
group; NaNO2: nitrite-donor sodium nitrite group; C-PTIO: organic NO scavenger 2-(4-
carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide group; POE-Hb: haem-
based NO scavenger pyridoxylated haemoglobin poly-oxoethylene group. Norm: 
normoxia; Hypo: hypoxia. NOx: total oxidation products (sum of nitrite and nitrate); 
RSNO: S-nitrosothiols; RNNO: N-nitrosamines; RXNO: total nitrosation products (sum of 
RSNO and RNNO). Dashed bars denote the hypoxic groups. *p<0.05 vs normoxia; #p<0.05 
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Figure 4: Erythrocytic metabolites related to oxidation of and nitrosation by NO 
NEPI: norepinephrine group; SEITU: non-selective NOS inhibitor S-ethyl-isothiourea 
group; NaNO2: nitrite-donor sodium nitrite group; C-PTIO: organic NO scavenger 2-(4-
carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide group; POE-Hb: haem-
based NO scavenger pyridoxylated haemoglobin poly-oxoethylene group. Norm: 
normoxia; Hypo: hypoxia. NOx: total oxidation products (sum of nitrite and nitrate); 
RSNO: S-nitrosothiols; RNNO: N-nitrosamines; RXNO: total nitrosation products (sum of 
RSNO and RNNO). Dashed bars denote the hypoxic groups. *p<0.05 vs normoxia; #p<0.05 
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Figure 5: Haem nitrosylation as  marker of NO availability in erythrocytes 
NEPI: norepinephrine group; SEITU: non-selective NOS inhibitor S-ethyl-isothiourea 
group; NaNO2: nitrite-donor sodium nitrite group; C-PTIO: organic NO scavenger 2-(4-
carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide group; POE-Hb: haem-
based NO scavenger pyridoxylated haemoglobin poly-oxoethylene group. NOHb: nitrosyl-
haemoglobin. *p<0.05 vs normoxia; #p<0.05 vs sham normoxia; °p<0.05 vs sham hypoxia. 
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Supplementary figure S1: Dose-response curves 
BL: baseline measurement; H/N: measurement after randomisation to hypoxia or 
normoxia. Open symbols represent normoxic rats, closed symbols are hypoxic rats. 
SHAM: normoxic and hypoxic control groups; SEITU: non-selective NOS inhibitor S-ethyl-
isothiourea group; NEPI: norepinephrine group; POE-Hb: haem-based NO scavenger 
pyridoxylated haemoglobin poly-oxoethylene group; C-PTIO: organic NO scavenger 2-(4-
carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide group; NaNO2: sodium 
nitrite group. N=4 animals per group. 
 
Supplementary figure S2: Dose-response to L-NAME 
BL: baseline measurement; H/N: measurement after randomisation to hypoxia or 
normoxia. Open symbols represent normoxic rats, closed symbols are hypoxic rats. L-
NAME: N (G)-nitro-L-arginine methyl ester. N=3 animals per group. 
 
Supplementary figure S3: Haemodynamic effects of NO scavenging after hypoxia and 
NOS inhibition and after hypoxia, NOS inhibition and nitrite administration 
BL: baseline measurement; SEITU:  non-selective NOS inhibitor S-ethyl-isothiourea; 
NaNO2: sodium nitrite; POE-Hb: haem-based NO scavenger pyridoxylated haemoglobin 
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